Disease · EFO_1001355
Laryngopharyngeal Reflux
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Laryngopharyngeal Reflux. Diseases, record EFO_1001355. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_1001355
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs9
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| LUCORIDALINES | CHEMBL5314637 | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| PANTOPRAZOLE | CHEMBL1502 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SODIUM ALGINATE | CHEMBL2108744 | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| TEGOPRAZAN | CHEMBL4297583 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RABEPRAZOLE | CHEMBL1219 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FOSAMPRENAVIR | CHEMBL1664 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LANSOPRAZOLE | CHEMBL480 | Small molecule | Phase 1 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| DEXLANSOPRAZOLE | CHEMBL1201863 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ESOMEPRAZOLE | CHEMBL1201320 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets2
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ATP4A | Potassium-transporting ATPase | 6 | Potassium-transporting ATPase blocker; Potassium-transporting ATPase inhibitor | Phase 3 | https://conductscience.org/library/genes/495 | Drugs and targets |
| ATP4B | Potassium-transporting ATPase | 6 | Potassium-transporting ATPase blocker; Potassium-transporting ATPase inhibitor | Phase 3 | https://conductscience.org/library/genes/496 | Drugs and targets |
Trials10
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00215787 | Investigation of the Association Between Nasal Polyposis and Extraesophageal Reflux Disease | Not applicable | 20 | 2010-09-22 | Nasal Polyps, Gastroesophageal Reflux | LANSOPRAZOLE | Its record names the disease | ClinicalTrials.gov |
| NCT01317472 | The Effects of Dexlansoprazole for the Treatment of Throat-Related Reflux | Not applicable | 11 | 2019-10-01 | Laryngopharyngeal Reflux | DEXLANSOPRAZOLE | Its record names the disease | ClinicalTrials.gov |
| NCT02533349 | Trial of Proton Pump Inhibitor With Prokinetics or Placebo in Patients With Laryngopharyngeal Reflux Disease | Phase 3 | 200 | Laryngopharyngeal Reflux Disease | LUCORIDALINES, PANTOPRAZOLE | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov | |
| NCT00274339 | Prevacid vs Lifestyle Modifications for the Treatment of LPR | Not applicable | 135 | Laryngopharyngeal Reflux | LANSOPRAZOLE | Its record names the disease | ClinicalTrials.gov | |
| NCT04383262 | Fosamprenavir for Laryngopharyngeal Upper Airway Tissue Treatment and Enzyme Reduction | Phase 2 | 104 | Laryngopharyngeal Reflux | FOSAMPRENAVIR | Its record names the disease | ClinicalTrials.gov | |
| NCT01450748 | Efficacy and Safety of Alginos Oral Suspension to Treat Laryngopharyngeal Reflux | Phase 3 | 80 | Laryngopharyngeal Reflux | SODIUM ALGINATE | Its record names the disease | ClinicalTrials.gov | |
| NCT00864396 | Twice Daily Prevacid for the Treatment of Laryngopharyngeal Reflux | Phase 1 | 59 | Laryngopharyngeal Reflux | LANSOPRAZOLE | Its record names the disease | ClinicalTrials.gov | |
| NCT05871398 | The Efficacy of Potassium-competitive Acid Blocker in Patients With Laryngopharyngeal Reflux Disease | Phase 3 | 36 | Laryngopharyngeal Reflux Disease | TEGOPRAZAN | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT01854970 | Benefit of Pharyngeal and Oesophageal pH-impedance of Patients With High Suspicion of Laryngopharyngeal Reflux | Not applicable | 30 | Laryngopharyngeal Reflux, Oesophageal pH-impedance | ESOMEPRAZOLE | Its record names the disease | ClinicalTrials.gov | |
| NCT00204698 | Laryngopharyngeal Reflux and Proton Pump Inhibitor (PPI) Treatment | Phase 2/3 | 24 | Laryngopharyngeal Reflux | RABEPRAZOLE | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials2
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Dexlansoprazole vs Sugar Pill: deaths from any cause | 0 of 9 | 0 of 2 | 11 | NCT01317472 | Trial comparisons |
| Dexlansoprazole vs Sugar Pill: serious adverse events | 0 of 9 | 0 of 2 | 11 | NCT01317472 | Trial comparisons |
Papers from its trials5
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/EFO_1001355
GET https://conductscience.org/api/diseases/v1/EFO_1001355/drugs